A Study to Assess the Safety and Performance of SurgiClot® in the Treatment of Cancellous Bone Bleeding

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-31

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this European study is to demonstrate the safety and performance of the SurgiClot® dressing in the treatment of cancellous bone bleeding.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Severe Soft Tissue Bleeding Study

NCT00977925

Soft Tissue Bleeding

COMPLETED PHASE3

The Fibrin Patch Soft Tissue Study

NCT00658723

Hemostasis

COMPLETED PHASE2

EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging

NCT05307783

Hemorrhage Bleeding Hemorrhage

COMPLETED

Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting

NCT03654560

Hemostasis Bleeding

COMPLETED NA

The Fibrin Pad Liver Study

NCT01166243

Hemorrhage

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients who require surgery for iliac crest bone graft (ICBG), pelvic osteotomy or spinal fusion will be screened for this multicenter, prospective, non-randomized, open-label study. All qualified subjects will be treated with the SurgiClot® haemostatic dressing (a completely soluble dressing consisting of solid nanofibers of electrospun dextran with embedded lyophilized human fibrinogen and thrombin proteins).

The safety and performance of the SurgiClot dressing will be evaluated in up to 40 subjects enrolled in Europe. Subjects will be followed for six weeks after the surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancellous Bone Bleeding

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SurgiClot

All qualified subjects will be treated with the SurgiClot haemostatic dressing

Group Type EXPERIMENTAL

SurgiClot haemostatic dressing

Intervention Type DEVICE

haemostatic dressing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SurgiClot haemostatic dressing

haemostatic dressing

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing a planned elective orthopaedic or spinal surgical procedure. Spinal surgery can be the entire spine although it should be confined to one or two-level fusions e.g. one or two level cervical, or thoracic or lumbar.
* Patient has an intraoperative bleeding site involving cancellous bone that the surgeon would typically treat with another topical haemostatic agent to control the bleeding.
* Patient has normal liver function
* The subject is willing and able to comply with the requirements of the study protocol, including the six weeks follow-up evaluation.

Exclusion Criteria

* Is unable or unwilling to return for the follow-up visit.
* The subject has had surgery at the intended application site ≤ 6 months before the current surgical procedure.
* Active infection at the surgical site.
* Pregnancy, as determined by urine pregnancy test, or breast feeding.
* Pre-operative platelet count \< 150,000, INR \> 1.3, and/or APTT \> 32.4.
* Pre-operative anaemia (Hb \< 110 g/L in females, Hb \< 120 g/L in males).
* Use of anticoagulant therapy (e.g., coumadin, heparin, clopidogrel), non-steroidal anti-inflammatory medications or fish oil supplements within 7 days of the surgery except for aspirin. (maximum dose 150 mg per day)
* Patient with a blood dyscrasia.
* Presence of a spinal tumour, intradural pathology, or prior spinal fusion surgery at the same target site.
* Participation in another clinical trial with an investigational drug or device within the past 30 days.
* Known allergy to human fibrinogen, human thrombin, or porcine-derived products.
* Compromised immune system.
* The use of a haemostatic agent is contraindicated for the subject.
* Fibrinolytic disorders requiring intraoperative antifibrinolytic treatment.
* Haematological disease (thromboembolic events, haemoglobinopathy, coagulopathy or haemolytic disease)
* Significant co-morbidities: Previous myocardial infarction (MI); severe ischemic heart disease (New York Heart Association Class III, IV); severe pulmonary disease; chronic renal failure; hepatic failure; uncontrolled hypertension.
* Subject is unwilling to receive blood products.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No